1. The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure
- Author
-
Najah Harouki, BS, Lionel Nicol, PhD, Isabelle Remy-Jouet, PhD, Jean-Paul Henry, BS, Anais Dumesnil, BS, Annie Lejeune, BS, Sylvanie Renet, BS, Francesca Golding, BS, Zoubir Djerada, PhD, Didier Wecker, PhD, Virginie Bolduc, PhD, Muriel Bouly, PhD, Jerome Roussel, PhD, Vincent Richard, PhD, and Paul Mulder, PhD
- Subjects
cardiovascular function ,heart failure ,IL-1β ,ischemia/reperfusion ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1β antibody gevokizumab improves ‘surrogate’ markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1β modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be determined.
- Published
- 2017
- Full Text
- View/download PDF